A Parallel-group, Randomized, Prospective, Interventional, Double-blind, Multicenter Global Phase 3 Study to Investigate the Efficacy and Safety of Finerenone Versus Placebo, in Addition to Standard of Care, in Participants With Chronic Kidney Disease and Type 1 Diabetes
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Finerenone (Primary)
- Indications Renal failure; Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms FINE-ONE
- Sponsors Bayer
Most Recent Events
- 25 Mar 2025 Planned End Date changed from 29 Oct 2025 to 26 Sep 2025.
- 25 Mar 2025 Planned primary completion date changed from 22 Sep 2025 to 22 Aug 2025.
- 26 Feb 2025 Status changed from recruiting to active, no longer recruiting.